B-SOFT(300451) 搜狐财经·2025-04-18 19:20Core Viewpoint - The company, Chuangye Huikang, has experienced a significant decline in both revenue and net profit for the year 2024, indicating challenges in its operational performance and market conditions [3]. Stockholder Changes - As of March 31, 2025, the number of shareholders increased to 82,400, up by 28,300 from December 31, 2024, representing a growth rate of 52.45%. The average number of shares held per shareholder decreased from 28,700 to 18,800, with an average holding value of 115,500 yuan [2][6]. Performance Disclosure - The company's main revenue for 2024 was 1.423 billion yuan, a year-on-year decrease of 11.96%. The net profit attributable to shareholders was -174 million yuan, down 572.96% year-on-year. The non-recurring net profit was -192 million yuan, a decline of 664.96%. In Q4 2024, the single-quarter main revenue was 254 million yuan, down 44.65%, with a net profit of -226 million yuan, a decrease of 313.73% [3][6]. Institutional Research Insights - During an investor communication meeting on April 14, the company explained that the decline in revenue was primarily due to strict budget controls and centralized procurement processes followed by public medical institutions, leading to longer procurement cycles. The company is committed to advancing its "Huikang Cloud" strategy, focusing on product quality and technological ecosystem development to meet user demands [4]. - The company launched the smart medical assistant MedCopilot in 2024, which integrates medical models and clinical data to support physicians with intelligent diagnostic assistance and electronic medical record management. This product has been implemented in various medical institutions [5][6]. - For 2025, the company plans to enhance its core business competitiveness by optimizing the technical architecture of its core systems and establishing standardized project implementation processes and quality control systems [5].